Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 7 November 1997:
Vol. 278. no. 5340, pp. 1064 - 1068
DOI: 10.1126/science.278.5340.1064
Prev | Table of Contents | Next

Articles

Integrating Genetic Approaches into the Discovery of Anticancer Drugs

Leland H. Hartwell, Philippe Szankasi, Christopher J. Roberts, Andrew W. Murray, Stephen H. Friend *

The discovery of anticancer drugs is now driven by the numerous molecular alterations identified in tumor cells over the past decade. To exploit these alterations, it is necessary to understand how they define a molecular context that allows increased sensitivity to particular compounds. Traditional genetic approaches together with the new wealth of genomic information for both human and model organisms open up strategies by which drugs can be profiled for their ability to selectively kill cells in a molecular context that matches those found in tumors. Similarly, it may be possible to identify and validate new targets for drugs that would selectively kill tumor cells with a particular molecular context. This article outlines some of the ways that yeast genetics can be used to streamline anticancer drug discovery.

L. H. Hartwell, P. Szankasi, and S. H. Friend are at the Seattle Project, Molecular Pharmacology Department, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. C. J. Roberts is at Rosetta Inpharmatics, Incorporated, 12040 115th Street NE, Kirkland, WA 98034, USA. A. W. Murray is in the Department of Physiology, University of California at San Francisco, 513 Parnassus Avenue, San Francisco, CA 94142-0444, USA.
*   To whom correspondence should be addressed.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair.
A. Ashworth (2008)
J. Clin. Oncol. 26, 3785-3790
   Abstract »    Full Text »    PDF »
Buffering of deoxyribonucleotide pool homeostasis by threonine metabolism.
J. L. Hartman IV (2007)
PNAS 104, 11700-11705
   Abstract »    Full Text »    PDF »
Tissue Plasminogen Activator Induces Pancreatic Cancer Cell Proliferation by a Non-Catalytic Mechanism That Requires Extracellular Signal-Regulated Kinase 1/2 Activation through Epidermal Growth Factor Receptor and Annexin A2.
E. Ortiz-Zapater, S. Peiro, O. Roda, J. M. Corominas, S. Aguilar, C. Ampurdanes, F. X. Real, and P. Navarro (2007)
Am. J. Pathol. 170, 1573-1584
   Abstract »    Full Text »    PDF »
Composite synthetic lethal identification of membrane traffic inhibitors.
M. C. Duncan, D. G. Ho, J. Huang, M. E. Jung, and G. S. Payne (2007)
PNAS 104, 6235-6240
   Abstract »    Full Text »    PDF »
Systematic genome instability screens in yeast and their potential relevance to cancer.
K. W. Y. Yuen, C. D. Warren, O. Chen, T. Kwok, P. Hieter, and F. A. Spencer (2007)
PNAS 104, 3925-3930
   Abstract »    Full Text »    PDF »
Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells.
A. V. Sarthy, S. E. Morgan-Lappe, D. Zakula, L. Vernetti, M. Schurdak, J. C.L. Packer, M. G. Anderson, S. Shirasawa, T. Sasazuki, and S. W. Fesik (2007)
Mol. Cancer Ther. 6, 269-276
   Abstract »    Full Text »    PDF »
Small Interfering RNA Screens Reveal Enhanced Cisplatin Cytotoxicity in Tumor Cells Having both BRCA Network and TP53 Disruptions.
S. R. Bartz, Z. Zhang, J. Burchard, M. Imakura, M. Martin, A. Palmieri, R. Needham, J. Guo, M. Gordon, N. Chung, et al. (2006)
Mol. Cell. Biol. 26, 9377-9386
   Abstract »    Full Text »    PDF »
Identification of an Agent Selectively Targeting DPC4 (Deleted in Pancreatic Cancer Locus 4)-Deficient Pancreatic Cancer Cells.
H. Wang, H. Han, and D. D. Von Hoff (2006)
Cancer Res. 66, 9722-9730
   Abstract »    Full Text »    PDF »
A Novel Yeast-Based Reporter Assay System for the Sensitive Detection of Genotoxic Agents Mediated by a DNA Damage-Inducible LexA-GAL4 Protein.
K. Ichikawa and T. Eki (2006)
J. Biochem. 139, 105-112
   Abstract »    Full Text »    PDF »
Multiple Repair Pathways Mediate Tolerance to Chemotherapeutic Cross-linking Agents in Vertebrate Cells.
K. Nojima, H. Hochegger, A. Saberi, T. Fukushima, K. Kikuchi, M. Yoshimura, B. J. Orelli, D. K. Bishop, S. Hirano, M. Ohzeki, et al. (2005)
Cancer Res. 65, 11704-11711
   Abstract »    Full Text »    PDF »
Combining biological networks to predict genetic interactions.
S. L. Wong, L. V. Zhang, A. H. Y. Tong, Z. Li, D. S. Goldberg, O. D. King, G. Lesage, M. Vidal, B. Andrews, H. Bussey, et al. (2004)
PNAS 101, 15682-15687
   Abstract »    Full Text »    PDF »
Potentiation of Cytotoxicity of Topoisomerase I Poison by Concurrent and Sequential Treatment with the Checkpoint Inhibitor UCN-01 Involves Disparate Mechanisms Resulting in Either p53-Independent Clonogenic Suppression or p53-Dependent Mitotic Catastrophe.
A. N. Tse and G. K. Schwartz (2004)
Cancer Res. 64, 6635-6644
   Abstract »    Full Text »    PDF »
Consequences of Nonadaptive Alterations in Cancer.
A. Kamb (2003)
Mol. Biol. Cell 14, 2201-2205
   Full Text »    PDF »
Disparity between DNA Base Excision Repair in Yeast and Mammals: Translational Implications.
M. R. Kelley, Y. W. Kow, and D. M. Wilson III (2003)
Cancer Res. 63, 549-554
   Abstract »    Full Text »    PDF »
In vivo genetics of anaesthetic action.
H. A. Nash (2002)
Br. J. Anaesth. 89, 143-155
   Abstract »    Full Text »    PDF »
Supramolecular Chemistry And Self-assembly Special Feature: Modulation of protein-protein interactions by synthetic receptors: Design of molecules that disrupt serine protease-proteinaceous inhibitor interaction.
H. S. Park, Q. Lin, and A. D. Hamilton (2002)
PNAS 99, 5105-5109
   Abstract »    Full Text »    PDF »
Selective Inhibition of MAPKK Wis1 in the Stress-activated MAPK Cascade of Schizosaccharomyces pombe by Novel Berberine Derivatives.
M. J. Jang, M. Jwa, J.-H. Kim, and K. Song (2002)
J. Biol. Chem. 277, 12388-12395
   Abstract »    Full Text »    PDF »
Evolution of Anticancer Drug Discovery and the Role of Cell-Based Screening.
F. M. Balis (2002)
J Natl Cancer Inst 94, 78-79
   Full Text »    PDF »
Systematic Genetic Analysis with Ordered Arrays of Yeast Deletion Mutants.
A. H. Y. Tong, M. Evangelista, A. B. Parsons, H. Xu, G. D. Bader, N. Page, M. Robinson, S. Raghibizadeh, C. W. V. Hogue, H. Bussey, et al. (2001)
Science 294, 2364-2368
   Abstract »    Full Text »    PDF »
High Throughput Studies of Gene Expression Using Green Fluorescent Protein-Oxidative Stress Promoter Probe Constructs The Potential for Living Chips.
C. R. Albano, C. Lu, W. E. Bentley, and G. Rao (2001)
J Biomol Screen 6, 421-428
   Abstract »    PDF »
Genetic synthetic lethality screen at the single gene level in cultured human cells.
A. H. Simons, N. Dafni, I. Dotan, Y. Oron, and D. Canaani (2001)
Nucleic Acids Res. 29, e100
   Abstract »    Full Text »    PDF »
SIR Functions Are Required for the Toleration of an Unrepaired Double-Strand Break in a Dispensable Yeast Chromosome.
C. B. Bennett, J. R. Snipe, J. W. Westmoreland, and M. A. Resnick (2001)
Mol. Cell. Biol. 21, 5359-5373
   Abstract »    Full Text »    PDF »
A White Paper: The Product of a Pancreas Cancer Think Tank.
S. Kern, R. Hruban, M. A. Hollingsworth, R. Brand, T. E. Adrian, E. Jaffee, and M. A. Tempero (2001)
Cancer Res. 61, 4923-4932
   Full Text »    PDF »
Antitumor Drug Adozelesin Differentially Affects Active and Silent Origins of DNA Replication in Yeast Checkpoint Kinase Mutants.
Y. Wang, T. A. Beerman, and D. Kowalski (2001)
Cancer Res. 61, 3787-3794
   Abstract »    Full Text »
Chromosome Instability and Defective Recombinational Repair in Knockout Mutants of the Five Rad51 Paralogs.
M. Takata, M. S. Sasaki, S. Tachiiri, T. Fukushima, E. Sonoda, D. Schild, L. H. Thompson, and S. Takeda (2001)
Mol. Cell. Biol. 21, 2858-2866
   Abstract »    Full Text »
The Rb/E2F pathway and cancer.
J. R. Nevins (2001)
Hum. Mol. Genet. 10, 699-703
   Abstract »    Full Text »    PDF »
Searching for Targets: The Power of Somatic Cell Genetics.
T. D. Tlsty (2001)
Genome Res. 11, 187-188
   Full Text »
Establishment of a Chemical Synthetic Lethality Screen in Cultured Human Cells.
A. Simons, N. Dafni, I. Dotan, Y. Oron, and D. Canaani (2001)
Genome Res. 11, 266-273
   Abstract »    Full Text »
Yeast Mutants As a Model System for Identification of Determinants of Chemosensitivity.
P. Perego, G. S. Jimenez, L. Gatti, S. B. Howell, and F. Zunino (2000)
Pharmacol. Rev. 52, 477-492
   Abstract »    Full Text »    PDF »
The Rad51 Paralog Rad51B Promotes Homologous Recombinational Repair.
M. Takata, M. S. Sasaki, E. Sonoda, T. Fukushima, C. Morrison, J. S. Albala, S. M. A. Swagemakers, R. Kanaar, L. H. Thompson, and S. Takeda (2000)
Mol. Cell. Biol. 20, 6476-6482
   Abstract »    Full Text »
Anticancer Agents Suppressive for Adult Parasites of Filariasis in Mongolian Jirds.
K. E. Kinnamon, R. R. Engle, B. T. Poon, W. Y. Ellis, J. W. McCall, and M. T. Dzimianski (2000)
Experimental Biology and Medicine 224, 45-49
   Abstract »    Full Text »
Mechanism-Based Target Identification and Drug Discovery in Cancer Research.
J. B. Gibbs (2000)
Science 287, 1969-1973
   Abstract »    Full Text »
Antifungal Activities of Antineoplastic Agents: Saccharomyces cerevisiae as a Model System To Study Drug Action.
M. E. Cardenas, M. C. Cruz, M. Del Poeta, N. Chung, J. R. Perfect, and J. Heitman (1999)
Clin. Microbiol. Rev. 12, 583-611
   Abstract »    Full Text »    PDF »
Rad18 Is Required for DNA Repair and Checkpoint Responses in Fission Yeast.
H. M. Verkade, S. J. Bugg, H. D. Lindsay, A. M. Carr, and M. J. O'Connell (1999)
Mol. Biol. Cell 10, 2905-2918
   Abstract »    Full Text »
The Topoisomerase-related Function Gene TRF4 Affects Cellular Sensitivity to the Antitumor Agent Camptothecin.
C. Walowsky, D. J. Fitzhugh, I. B. Castano, J. Y. Ju, N. A. Levin, and M. F. Christman (1999)
J. Biol. Chem. 274, 7302-7308
   Abstract »    Full Text »    PDF »
Requirement for p53 and p21 to Sustain G2 Arrest After DNA Damage.
F. Bunz, A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou, J. P. Brown, J. M. Sedivy, K. W. Kinzler, and B. Vogelstein (1998)
Science 282, 1497-1501
   Abstract »    Full Text »
Second Site Suppressor Mutations of a GTPase-deficient G-Protein alpha -Subunit. SELECTIVE INHIBITION OF Gbeta gamma -MEDIATED SIGNALING.
D. M. Apanovitch, T. Iiri, T. Karasawa, H. R. Bourne, and H. G. Dohlman (1998)
J. Biol. Chem. 273, 28597-28602
   Abstract »    Full Text »    PDF »
Sensitivity to Cisplatin and Platinum-Containing Compounds of Schizosaccharomyces pombe Rad Mutants.
P. Perego, F. Zunino, N. Carenini, F. Giuliani, S. Spinelli, and S. B. Howell (1998)
Mol. Pharmacol. 54, 213-219
   Abstract »    Full Text »
High-Density Cell Microarrays for Parallel Functional Determinations.
C. W. Xu (2002)
Genome Res. 12, 482-486
   Abstract »    Full Text »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)